Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1710)	12/1/2006 9:22:30 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MGRM Is due to open on an upgap after some news,reversing yesterday's dip.<g> It announced that PFE plans to establish a multi-national Expanded Access Program (EAP) that will make its investigational CCR5 antagonist maraviroc available to HIV/AIDS patients who have limited treatment options due to resistance or intolerance. (MGRM's co-receptor tropism assay, (Trofile), was used for patient selection.) Last month MRGM secured a 10M credit line from MER & had a "buy" recommendation from LAZ & this week also from CE Unterberg Towbin.<g> On a close above $2 it may get to retest its Oct.5 spike at the 2.70 level.<g> bigcharts.marketwatch.com MRGM has a small LTD, trades around 5.2xBV & has a short position close to 16x its daily average volume.The list of institutional & mutual fund holders is pretty good for a stock of this price level.<g> finance.yahoo.com Its LTC is "interesting" <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1710)	7/17/2007 4:39:54 PM
From: Jibacoa	Respond to of 3722

DRRX Also had a good move today after it announced positive results from a 122 patient PIIb of POSIDUR for treatment of post-operative pain in patients undergoing inguinal herniorrhaphy The stock was up 19.3% at its intraday H of $4.45 at which it traded at 12:45PM & 1:10PM. The UG remained unclosed & the stock was up 18.23% for the day & still trying to retest its intraday H AHs.<g> bigcharts.marketwatch.com With the positive results of the PIIb of POSIDUR, DRRX is due to receive $8M "milestone payment" from NTMD, which is a collaborator in the trial. With some further good news DRRX could start getting off its longer term DT coming from its Sep-Oct double top at the $7.40 level.<g> bigcharts.marketwatch.com I am more interested in NTMD, which has been trimming its losses consistently, had better revenues on the 1stQ & had some deals with ELN on Feb12 Bernard